Alexion Defies Biotech's Slow Sales Trend; Beats Estimates

Boggs, Jennifer
July 2011
BioWorld Today;7/22/2011, Vol. 22 Issue 141, p1
The article reports on the second quarter earnings of Alexion Pharmaceuticals Inc. in 2011, which prompted the company to increase the sales guidance for its paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris. The price of the stocks of the company rose 9 percent on July 21, 2011 to close at 56.77 U.S. dollar. The revenues posted by Alexion in the first quarter of 2011 is 48 percent higher than the same period in 2010. Information on the efforts made by the company to expand Soliris is also presented.


Related Articles

  • EARNINGS ROUNDUP.  // BioWorld Today;10/27/2008, Vol. 19 Issue 209, p3 

    The article reports that Alexion Pharmaceuticals Inc. of Cheshire, Connecticut reported total revenue of $76.5 million for the third quarter of 2008. According to the article, this came from sales of paroxysmal nocturnal hemoglobinuria drug Soliris which were up from the $21.8 milion in revenues...

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates.  // Bioworld Week;7/25/2011, Vol. 19 Issue 30, p5 

    The article reports on the slow sales trend of drug Soliris (eculizumab) manufactured by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut for the treatment of paroxysmal nocturnal hemoglobinuria.

  • Alexion Reports 3rd Qtr 2011 Results.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p841 

    The article reports on the announcement of Alexion Pharmaceuticals Inc. for its financial results for the 3 and 9 months that ended September 30, 2011 in Cheshire, Connecticut. The company has reported 204.0 million U.S. dollar total revenues in the third quarter of 2010 from net product sales...

  • Alexion Gets FDA Nod For Soliris; First Drug For PNH. Boggs, Jennifer // BioWorld Today;3/19/2007, Vol. 18 Issue 53, p1 

    The article reports that the monoclonal antibody product Soliris from Alexion Pharmaceuticals won U.S. Food and Drug Administration approval in paroxysmal nocturnal hemoglobinuria (PNH), making it the first therapy indicated for the rare genetic disorder. The news boosted the shares of Alexion...

  • An Orphan's Tale. Comer, Ben // Medical Marketing & Media;Nov2009, Vol. 44 Issue 11, p48 

    The article offers information on Soliris, a drug manufactured and marketed by Alexion Pharmaceuticals Inc. in the U.S. It notes that the drug is monoclonal antibody indicated for the treatment of paroxysman nocturnal hemoglobinuria (PNH) and was designated an orphan drug by the U.S. Food and...

  • Alexion, Others Show Resilience After Breakouts. KEN SHREVE // Investors Business Daily;12/3/2014, pB08 

    Stocks that show resilience and trade tightly after a are worth watching. Why? Because price action like this can often a new entry after an initial breakout.

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/30/2009, Vol. 20 Issue 19, p2 

    This section offers news briefs on the biopharmaceutical industry. The European Union (EU) has approved the use of Zavesca from Actelion Ltd. in treating progressive neurological manifestations of Niemann-Picktype C disease. Alexion Pharmaceuticals Inc. has announced that Health Canada approved...

  • Earnings Roundup.  // BioWorld Today;7/26/2012, Vol. 23 Issue 144, p7 

    The article focuses on the 274.7 million U.S. dollars net product sales of Soliris (ecuilizumab) reported by Alexion Pharmaceuticals Inc. for the second quarter of 2012.

  • EARNINGS.  // BioWorld Today;7/26/2013, Vol. 24 Issue 142, p7 

    The article reports that the net product sales of Soliris drug by biopharmaceutical firm Alexion Pharmaceuticals Inc. has reached 370 dollars for the second quarter of 2013.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics